FGF7/Keratinocyte growth factor (KGF) regulates the dierentiation and development of the prostate epithelium, while over-expression of FGF8 and FGF1 are implicated in carcinogenesis of the prostate. We tested the hypothesis that dierent members of the FGF family function through dierent signalling molecules. In prostate DU145 cells, both FGF1 and FGF2 activated ERK1/2 potently and p38 moderately. KGF was however most ecient in inducing p38 activities but had no eect on ERK1/2 function. JNK and STAT activities were not induced by FGFs in prostate cells. In vitro expression of the transcription factors Elk-1 and MEF2A (substrates for ERK1/2 and p38, respectively) for functional quanti®cation, con®rmed the pattern of FGF-induced MAPK activations in COS-7 cells. Furthermore, KGF was more ecient than FGF1 and FGF2 in inducing actin stress ®bres, and the speci®c p38 inhibitor SB202190 completely abolished this in a dose-dependent manner. The MEK1/2 inhibitor, U0126, had no eect on FGF-induced stress ®bre formation. This study demonstrates the selective activation of MAPK family members by FGFs resulting in activation of transcription factors and stress ®bre formation. As multiple FGFs are overexpressed in human prostate cancer, characterization of the distinct signalling pathway by FGFs may reveal new speci®c targets for therapy. Oncogene (2001) 20, 5359 ± 5365.
, epidermal growth factor (EGF) and insulin-like growth factors (IGFs), are thought to contribute towards both the development and progression of prostate cancer (Byrne et al., 1996) . Better understanding of the signalling events resulting from aberrant expression of peptide growth factors may form the basis of improved targets for new treatment protocols.
The family of FGFs represents a group of related polypeptides aecting a wide variety of biological processes (Yamasaki et al., 1996; Smallwood et al., 1996) . Multiple members of FGFs are co-expressed in prostate cancer (Dorkin et al., 1998 (Dorkin et al., , 1999 . We have previously demonstrated over-expression of FGF8, or androgen-induced growth factor, in prostate cancer. High levels of FGF8 expression were strongly associated with high grade and high stage disease (P50.0001 and P50.001, respectively). Furthermore, aberrant FGF8 expression was associated with a poor survival, remaining signi®cant with follow up in excess of 10 years (Dorkin et al., 1998) . More recently, we have identi®ed co-expression of FGF1 and FGF2 along with FGF8 in a signi®cant percentage of resected prostate tumours (Dorkin et al., 1999) . Keratinocyte growth factor (KGF/FGF7) is expressed in both benign prostatic hyperplasia (BPH) and prostate cancer regulating the dierentiation and development of the prostate epithelium. However, its precise role in prostate tumorigenesis remains unclear as some studies highlight the expression of KGF transcripts in mainly stromal cells and not in epithelial cells (Leung et al., 1997; Ittman and Mansukhani, 1997) , others report ®ndings of KGF expression in both cells types McGarvey and Stearns, 1995) .
FGFs interact with their high anity receptor tyrosine kinases to activate downstream events. The four FGFR genes encode receptors with an extracellular ligand-binding region composed of up to three immunoglobulin-like domains (Ig), a single transmembranous region, and a cytoplasmic region containing tyrosine kinase activity. Multiple receptor isoforms are produced following splicing modi®cations, of which alternative exon splicing of the third immunoglobulinlike domain (IgIII) controls their ligand binding anities.
It is not clear whether there are synergistic eects among dierent FGFs, or whether distinct downstream events may result from simultaneous activation of the FGFR system by multiple FGFs. Aspects of FGFRinduced signalling events have been examined but the mechanism by which dierent FGFs regulate multiple functions that are important in the progression of prostate cancer remains poorly understood. PLCg associates with Tyrosine 766 on FGFR1 (Mohammadi et al., 1992) and its activity is induced following FGFR activation resulting in phosphatidylinositol turnover. Activation of PLCg is, however, not required for FGFinduced proliferation (Peters et al., 1992) or chemotaxis (Landgren et al., 1998) . FGF1 induced Src activity results in cytoskeletal remodelling and cell migration in Swiss 3T3 cells (LaVallee et al., 1998) . Signalling activities of the FGFR system may also involve FRS2, a lipid anchored molecule, which is recruited to the activated FGFR and binds to the adaptor protein Grb2 (Kouhara et al., 1997) .
Characterization of the signalling pathways associated with particular FGFs may allow better understanding of the pathobiology in prostate cancer as well as the development of novel therapeutic agents. The aim of the present study was to investigate the signalling events resulting from FGFR activation by dierent members of FGF in human prostate cells. We chose the DU145 human prostate cancer cell line and challenged it with FGF1, FGF2 or KGF. FGF1 binds to all known FGFRs. KGF binds speci®cally to the IIIb isoform of the FGFR2 gene, while FGF2 binds to the IIIc isoform of FGFR2 as well as other FGFR gene products (Miki et al., 1992) . DU145 cells are known to express FGFR1, FGFR2IIIb, FGFR2IIIc and FGFR4 (Carstens et al., 1997; Chandler et al., 1999) . Three subclasses of MAPKs (namely ERK, JNK and p38), as well as the signal transducers and activators of transcription (STATs) 1, 3 and 5 were studied along with the corresponding downstream events.
FGF1 and FGF2 both stimulated ERK1/2 phosphorylation ( Figure 1A ). There was an equal stimulation of ERK1/2 by both TPA and serum compared to the preferential stimulation of ERK2 by FGF1 and FGF2. KGF did not stimulate either ERK 1 or ERK 2 phosphorylation. Results from the in vitro kinase assays for p38 activity showed that KGF induced the highest level of p38 activation (12-fold activation) while treatment with FGF1 and FGF2 only resulted in moderate activation (2.8-and ®vefold activation, respectively) ( Figure 1B) . Interestingly, the relative activation of p38 by KGF was higher than that by the positive control, sorbitol (12-fold compared to 8.5-fold, respectively). In a time course experiment over 2 h KGF did not stimulate ERK activity in DU145 cells ( Figure 1c ). KGF pretreatment failed to inhibit FGF1-induced ERK 1/2 activation (data not shown).
Ets transcription factors are implicated in the regulation of FGF responsive genes such as matrixmetalloproteinase-1 (Newberry et al., 1997) . Veri®ca-tion of the activation of downstream kinase substrates was assessed by transient transfection of Elk-1 and GAL4-MEF2A expression plasmids into monkey kidney COS-7 and human prostate DU145 cells. Following normalization by assessment of co-transfected b-galactosidase activity, COS-7 cells were selected for subsequent experiments as they provided the higher level of construct expression required. The cfos Serum Response Element (SRE) binds a transcription factor complex comprising Serum Responsive Factor (SRF) and one of the three Ets domain accessory proteins, the Ternary Complex Factors (TCFs) Elk-1, SAP-1 or SAP-2 (Ling et al., 1997; Treisman, 1995) . Both SRF and the TCFs are targets for signal transduction pathways (Price et al., 1996) . Activating phosphorylation of Elk-1 is mediated mainly by ERK1/2 and JNK.
Following transient transfection of FLAG-tagged Elk-1 into COS-7 cells, FGF1 and FGF2 induced an increase in Elk-1 phosphorylation (22.9 and 8.9, To determine ERK1/2 activity, lysates were separated by SDS ± PAGE (10% gel) and immunoblotted. ERK1/2 kinase activities were determined by probing with anti-phosphoERK (pERK) (Santa Cruz). 12-Otetradecanoylphorbol-13-acetate (TPA) was included as a positive control for ERK1/2 activity (Dieckgraefe et al., 1997) . ERK loading was assessed by probing with anti-ERK1 (Santa Cruz). Relative activities, determined using densitometry, are shown at the bottom. (B) FGF-induced p38 activity. Serum-starved cells (7) were prepared as described in A. p38 activity was determined by in vitro protein kinase assay, as previously described (Jiang et al., 1997) , incorporating myelin basic protein (MBP) as a substrate. Sorbitol was used as a positive control for p38 activity (Jiang et al., 1999) . Loading was determined by probing half the immunoprecipitate with anti-p38 (Upstate Biotechnology). Relative activities, determined using densitometry, are shown at the bottom. (c) KGF time-course experiment. Serum-starved DU145 cells were treated for 0 ± 120 min with 0.1 nM KGF or for 15 min with FGF1, FGF2 or serum before determining ERK1/2 activity as described in A. The histogram represents fold ERK1/2 activity against the control (time=0 min) following correction for ERK1 protein loading as determined by densitometry. For all ®gures the experiments were performed in at least triplicate respectively) (Figure 2A ). There was no detectable phosphorylation of Elk-1 in either uninduced or KGF treated cells. The chemical inhibitor U0126, a potent inhibitor of MEK1/2, signi®cantly blocked FGF1-and FGF2-induced phosphorylation of Elk-1.
MEF2A, a member of the MADS-box family of transcription factors, regulates the expression of muscle-speci®c genes (Kaushal et al., 1994) and has been shown to be a substrate for p38 MAPK (Yang et al., 1999) . FGF-induced p38 activities were quanti®ed by transfected GAL4-driven transcription assays mediated by either GAL4-MEF2A or GAL4-ME-F2ADD fusion proteins (where DD construct lacks the p38 docking domain). The highest level of p38 activity was seen in response to KGF while FGF1 and FGF2 treatment resulted in moderate levels of p38 activation ( Figure 2B ), supporting data from the in vitro kinase assay (see Figure 1B) . Deletion of the p38 docking site within the MEF2A gene completely abolished KGF-induced MEF2A activation. Together, these studies imply that FGF1 and FGF2 activate Elk-1 (via the ERK1/2), while KGF activates MEF2A (via p38 MAPK) to a greater level compared to FGF1 and FGF2. None of the three FGFs tested had any signi®cant eects on JNK or STAT 1, 3 and 5 activities in DU145 cells (data not shown). Although we acknowledge that the FGFR expression pro®le in COS-7 cells has not been fully characterized, the pattern of FGF-induced Elk-1 and MEF2A activities in these cells mirrored those observed in DU145 cells. Hence, the model of selective MAPK activation applies to two dierent cell types.
To determine if MAPK activation by FGF resulted in a physiologically signi®cant change, we addressed the level of F-actin reorganization in DU145 cells following treatment by FGFs. Changes in membrane structure, such as ruing and blebbing, and associated actin ®lament reorganization can occur within minutes of stimulation by growth factors or cytokines (Brunk et al., 1976; Ridley, 1994) . Membrane blebs are distinguishable from rues or lamellipodia as they do not contain phalloidin-detectable actin (Velmuri et al., 1996) . DU145 cells treated with FGFs, namely FGF1, FGF2 and KGF, did not show any evidence of membrane blebbing or ruing on scanning electron microscopy (data not shown). However, reorganization of actin ®laments and changes in cell morphology were dierentially regulated by FGFs. At 0.1 nM, KGF induced the formation of coarse bundles of actin ®bres. Higher concentration of KGF at 0.3 nM resulted in further actin reorganization with spreading of a network of less coarse actin ®laments throughout the cytoplasm ( Figure 3G and H, respectively). KGF treatment did not alter membrane contours or induce the formation of focal adhesion points. Compared to KGF, both FGF1 and FGF2 were less ecient in inducing coarse stress ®bres. Fine stress ®bres were induced by FGF1 at concentration of 0.19 nM, and further increase in FGF1 concentration to 0.54 nM did not show any additional changes ( Figure 3C and D, respectively). Neither concentrations of FGF1 used ( Figure 3C and D) resulted in the extensive reorganization of actin ®laments observed following treatments of cells with the lowest concentration of KGF ( Figure 3G ). FGF2 treatment at low concentration of 0.16 nM resulted in the formation of actin plaques and membrane retraction. A higher concentration of FGF2 (0.48 nM) was able to induce the formation of coarse stress ®bres but appeared to have lost its eect on the membrane contour ( Figure 3E and F, respectively) .
The potency of FGF-induced stress ®bre formation mirrored that of the dierential abilities of FGFs to activate p38, with KGF being most potent. Using the speci®c p38 inhibitor, SB202190, FGF-induced stress ®bre formations were completely abolished in a dosedependent manner, con®rming the p38-dependent nature of the FGF-induced cytoskeletal changes. At 5 mM, the inhibitor diminished the formation of actin stress ®bres ( Figure 4C , D, and F, respectively), while at 25 mM, the inhibitor completely abolished all stress ®bre formation ( Figure 4E and G, respectively). None (Yang et al., 1998) . Transfections were carried out using Superfect reagent and as described by the manufacturer (Qiagen). Serum-starved cells were induced with FGFs or serum for 30 min before cell lysates were obtained and subjected to SDS ± PAGE. Blots were probed with an anti-active Elk-1 (Ser383) antibody. Normalization of protein loading was assessed by probing for FLAG expression with an M2 antibody (Sigma). For experiments involving treatment with U0126, cells were pretreated with 10 mM inhibitor or DMSO (control) for 30 min before induction with FGF. Relative activities of Elk-1, determined using densitometry, are shown at the bottom of the ®gure. Results shown are representative of three independent experiments. (B) COS-7 cells were co-transfected with expression vectors encoding GAL-MEF2A or GAL-MEF2ADD with a GAL4-driven luciferase reporter plasmid (DD signi®es the deletion of the p38 docking domain), as described previously (Yang et al., 1999) . Serumstarved cells were induced with FGFs or serum for 30 min before luciferase activity was determined. Eects of FGFs on the cytoskeleton structure and cellular morphology are not well documented. We describe our ®ndings on the patterns of induction of actin ®bres following treatment with dierent FGFs, Figure 4 FGF-induced actin stress ®bres are blocked by the p38 inhibitor SB202190. Serum-starved DU145 cells were treated with SB202190, a speci®c p38 inhibitor (Calbiochem), for 1 h prior to FGF treatment and then stained for F-actin as described in Figure  3 ). Five mM of inhibitor was used in A, B, C, D, and F, and 25 mM in E and G. and observed a potential correlation to the pro®le of p38 activation by the three FGFs tested. In human endothelial cells, Cdc42, Rac and Rho are activated in a hierarchical cascade following stimulation with Tumour Necrosis Factor-a leading to actomyosinmediated cell retraction and formation of intercellular gaps (Wojciak-Stothard et al., 1998) . Activated RhoA is particularly ecient in inducing polymerized actin, formation of stress ®bres and cell retraction. When compared to RhoA, both Cdc42 and Rac proteins induce less dramatic changes in the above parameters but in addition induce formation of ®lopodia and lamellipodia. The role of RhoA in the induction of actin stress ®bres has also been con®rmed in the TRAMP murine prostate tumour cell line whereby expression of dominant-negative RhoA (T19N) in these cells caused slower growth and fewer actin-stress ®bres to form. These eects were reversed by expression of a constitutively active form of RhoA (Ghosh et al., 1999) . With the absence of membrane ruing and lamellipodia, our ®ndings are consistent with a model where Rho acts upstream of p38 to mediate FGFinduced cytoskeleton changes. Activation of stress-®bre assembly by RhoA in TRAMP cells is proposed as a requirement by the cells to enable cell cycle progression (Ghosh et al., 1999) .
In a rat prostate cancer model, FGFR2IIIb is preferentially expressed in well dierentiated androgen-responsive tumour cells (Type I). In contrast, in poorly dierentiated hormone-insensitive tumour cells (Type II), there is a concurrent reduction of FGFR2 gene expression and activation of FGFR1 expression (Yan et al., 1993) . The introduction of FGFR1 into Type I cells rapidly increases their malignant progression . Furthermore, the overall rate of cell growth was reduced upon restoration of FGFR2IIIb in Type II cells (Matsubara et al., 1999) . These observations suggest the distinct roles of FGFR1 and FGFR2 in prostate cancer: FGFR1 increases and FGFR2 inhibits malignant cell growth. The patterns of MAPK activity may likely re¯ect the signalling characteristics of the FGFR expressed within the prostate. In summary, we have shown evidence to support the hypothesis that members of the FGF family function through dierent signalling molecules in DU145 prostate cancer cells. Abbreviations FGF, ®broblast growth factor; KGF, keratinocyte growth factor; FGFR, FGF receptor; MAPK, mitogen-activated protein kinase; ERK, extracellular signal-regulated protein kinase; JNK, c-Jun N-terminal kinase; STATs, signal transducers and activators of transcription; PLC-g, phospholipase C gamma; FRS2, FGFR substrate-2; BPH, benign prostatic hyperplasia, FCS, foetal calf serum; MEF2A, Muscle enhancer factor-2A.
